Octagam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Octagam, is an immunoglobulin presented as a sterile solution for intravenous use. It replaces deficient antibodies and is used in primary immunodeficiency disorders and certain immune‑mediated conditions in both children and adults.

GNH USA supplies Octagam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Octagam is an immunoglobulin therapy that modulates the immune system in several recognized clinical settings. - Primary immunodeficiency diseases: provides the missing antibodies to reduce infection frequency. - Chronic immune thrombocytopenia (ITP): helps raise platelet counts and lessen bleeding risk. - Multifocal motor neuropathy (MMN): improves muscle strength and functional ability. - Kawasaki disease with coronary artery involvement: reduces inflammation and aneurysm progression. - Hemolytic disease of the newborn (HDN) due to ABO incompatibility: limits hemolysis when standard therapies are insufficient.

Adverse reactions to Octagam vary from mild to severe and are monitored during and after infusion.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: typically occurring during the first infusion. - Nausea or vomiting: may accompany infusion reactions. - Fatigue: general tiredness reported by some patients. - Injection site discomfort: pain or erythema at the infusion site. - Hypertension: transient rise in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Acute renal failure: rare but serious kidney injury. - Thromboembolic events: clot formation in veins or arteries. - Hemolytic transfusion reactions: immune‑mediated destruction of red blood cells. - Aseptic meningitis: inflammation of the meninges without infection. - Severe thrombocytopenia: sudden drop in platelet count.

Before initiating Octagam therapy, clinicians should assess patient history and monitor for specific risks. - Screen for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions. - Evaluate renal function: adjust infusion rate in patients with impaired kidney function. - Monitor for thrombotic risk: consider prophylaxis in high‑risk individuals. - Observe during infusion: watch for signs of anaphylaxis or acute reactions. - Avoid rapid infusion rates: slower rates reduce incidence of adverse events. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid): - Live vaccines: concurrent use can diminish vaccine efficacy and increase infection risk. - High‑dose aspirin or other NSAIDs: may increase bleeding tendency during infusion. - Rituximab or other B‑cell depleting agents: can alter IgG pharmacokinetics and efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, DOACs): monitor coagulation parameters as immunoglobulin can affect clotting factors. - Corticosteroids: may mask early signs of infusion reactions. - Diuretics: watch for fluid shifts and blood pressure changes during infusion.